EMA asks for feedback on their regulatory science strategy
EMA seeks your expertise, your opinion and your feedback on their draft strategic reflection ‘Regulatory Science to 2025’. This document sets out a strategy for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. HollandBIO encourages everyone to fill in this consultation, as this strategy will help shape the vision for the next EU Medicines Agencies Network Strategy (2020–2025).
“The Regulatory Science strategy to 2025 aims to build a more adaptive regulatory system that will encourage innovation,” said Guido Rasi, EMA’s Executive Director. “The strategy includes developments and challenges in medicines development that we together with experts identified in a thorough process of mapping and selection. Now we want to hear from our stakeholders whether they consider this strategy ambitious enough.”
As a well-organized adaptive ecosystem also lies at the heart of HollandBIO’s programme “faster and better from bench to bedside”, we kindly encourage all of you to provide feedback to the five strategic goals the Agency proposes:
- catalysing the integration of science and technology in medicine development;
- driving collaborative evidence generation – improving the scientific quality of evaluations;
- advancing patient-centred access to medicines in partnership with healthcare systems (for human medicines only);
- addressing emerging health threats;
- enabling and leveraging research and innovation in regulatory science.
You are kindly invited to send in your comments to the strategy by 30 June 2019 latest via this online questionnaire.
